Onychomycosis;Onychomykose

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 1, 2007, Pages 61-66

  Seebacher, Claus ^a   Brasch, Jochen ^a   Abeck, Dietrich ^a   Cornely, Oliver ^a   Effendy, Isaak ^a   Ginter Hanselmayer, Gabriele ^a   Haake, Norbert ^a   Hamm, Gudrun ^a   Hipler, Uta Christina ^a   Hof, Herbert ^a   Korting, Hans Christian ^a   Mayser, Peter ^a   Ruhnke, Markus ^a   Schlacke, Kurt Heiner ^a   Tietz, Hans Jörgen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; TERBINAFINE; UREA;

CANDIDA ALBICANS; DIFFERENTIAL DIAGNOSIS; DYSTROPHIC ONYCHOMYCOSIS; FUNGUS CULTURE; HISTOLOGY; HUMAN; LABORATORY TEST; LEUKONYCHIA TRICHOPHYTICA; MICROSCOPY; MONOTHERAPY; MYCOSIS; ONYCHOMYCOSIS; REPEATED DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; DERMATOLOGIC AGENTS; DERMATOLOGY; HUMANS; ONYCHOMYCOSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33846161968     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06134.x     Document Type: Review

References (41)

1. Abeck D, Haneke E, Nolting S, Reinel D, Seebacher C (2000) Onychomykose. Dt Ärztebl 97: A 1984-1986.
2. Amichai B, Shiri J (1999) Fluconazole 50 mg/day therapy in the management of chronic paronychia. J Dermatol Treatm. 10: 199-200.
3. Avner S, Nir N, Henri T (2005) Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatol Treatment 16: 327-330.
4. Baran R, Feuilhade M, Datry A, Goettmann S, Pietrini P, Viguie C, Badillet G, Larnier C, Czernielewski J (2000) A randomized trial of amorolfine 5 % solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 142: 1177-1183.
5. Baran R, Kaoukhov A (2005) Topical antifungal drugs for the treatment of onychomycosis: an overview of current srategies for monotherapy and combination therapy. JEADV 19: 21-29.
6. Bräutigam M, Nolting S, Schopf RE, Weidinger G for the Seventh Lamisil® German Onychomycosis Study Group (1995) Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 311: 919-22.
7. De Cyper C, Hindryckx PHFB (1999) Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 141 (Suppl 56): 15-20.
8. Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D, Scher RK, Martin AG, Pariser DM, Pariser RJ, Ellis CN, Kang S, Katz HI, McDonald JC, Muglia J, Savon RC, Webster G, Elewski BE, Leyden JJ, Bucko AD, Tschen EH, Hanifin JM, Morman MR, Shupack JL, Levine N, Lowe NJ, Bergfeld WF, Camisa C, Feingold DS, Konnikow N, Odom RB, Aly R, Greer DL (1998) Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 38 (Suppl): 87-94.
9. Effendy I, Gasse A, Stangier U (1991) Wann ist eine alleinige topische Behandlung bei Onychomykosen sinnvoll? Z Hautkr 66: 620-627.
10. Effendy I, Strassman K (1999) Longitudinal studies on survivability and antifungal susceptibility of dermatophytes causing toenail mycosis. Mycoses 42:172-173.
11. Epstein E (1998) How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 134: 1551-1554.
12. Evans EGV, Sigurgeirsson B (1999) Double blind, randomised study comparing continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis. Br Med J 318: 1031-1035.
13. Frankum LE, Nightengale B, Russo CL, Sarnes M (2005) Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomykosis. Managed care interface 18: 55-63.
14. Fräki JE, Heikkila HT, Kero MO, Kuokkanen KE, Oksman RO, Rantanen TT, Saari SS, Sten ML, Stubb SHA, Uggeldahl PE (1997) An open-label, noncomparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. Cur Ther Res 58: 481-491.
15. Ginter G, De Doncker P (1998) An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. Mycoses 41: 235-238.
16. Grimmer H (1962) Histologische Untersuchungen bei Nagelmykosen. In: Götz H (Hrsg) Die Griseofulvinbehandlung der Dermatomykosen. Springer, Berlin Göttingen Heidelberg, S 74-78.
17. Gupta AK, Lambert J (1999) Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. Int J Dermatol 38 (Suppl. 2): 53-64.
18. Gupta AK, Gregurek-Novak T (2001) Efficacy of itraconazole,terbinafine, fluconazole, griseofulvin and ketoconazole in treatment of Scopulariopsis brevicaulis onychomycosis of the toes. Dermatology 202: 235-238.
19. Haneke E.: Epidemiologie und Pathologie der Onychomykosen. In Nolting, S., Korting, H.C. (Hrsg.): Onychomykosen. Berlin Heidelberg New York London Paris Tokyo Hong Kong, Springer 1989.
20. Haase G., Borg-von Zepelin M., Bernhardt H., Fegeler W., Harmsen D., Kappe R., Korting H.C., Kuijpers A., Schaller M., Schmalreck A., Seebacher C., Tintelnot K. (2001) Qualitätsstandards in der mikrobiologischen Diagnostik. Pilzinfektionen Teil I Präanalytik, Analytik (MiQ 14), Pilzinfektionen Teil II Spezielle Pilzdiagnostik (MiQ 15). München Jena, Urban & Fischer.
21. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran N (2005) Treatment options-development of consensus guidelines. JEADV 19 (Suppl. 1): 25-33
22. Montero-Gei F, Robles-Soto ME, Schlager H (1996) Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 35: 587-588.
23. Nolting S (1999) Open Studies of Ciclopirox Nail Lacquer in Onychomycosis- A Review. In Shuster S (ed) Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis. Springer, Berlin Heidelberg New York 1999 S. 75-80.
24. Osborne CS, Leitner I, Favre B, Ryder NS (2004) Antifungal drug response in an in vitro model of dermatophyte nail infection. Medical Mycology 42: 159-163.
25. Ossowski B, Duchmann U (1997) Der Einfluß des haushaltsü blichen Waschprozesses auf mykotisch kontaminierte Textilien. Hautarzt 48: 397-401.
26. Reichenberger M, Götz H (1962) Zur Therapie der Tinea unguium mit Griseofulvin. In: Götz H (Hrsg) Die Griseofulvinbehandlung der Dermatomykosen. Berlin Göttingen Heidelberg, Springer, S 68-71.
27. Reinel D, Clarke C (1992) Comperative efficacy and safty of amorolfine nail lacquer 5 % in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 17 (Suppl. 1) 44-49.
28. Roberts DT, Evans EGV (1998) Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 138: 189-190.
29. Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, Shupack JL, Pinnell S, Levine N, Lowe NJ, Aly R, Odom RB, Greer DL, Morman, MR, Bucko AD, Tschen EH, Elewski BE, Smith EB (1998) Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 38 (Suppl): 77-85.
30. Scher R (1999) Clinical efficacy of topical ciclopirox nail lacquer: Double-blind United States studies on onychomycosis. In Shuster S (ed) Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis. Springer, Berlin Heidelberg New York 1999 S. 62-68.
31. Seebacher C (1998) Grenzen der Kurzzeitbehandlung von Onychomykosen. Hautarzt 49: 705-708.
32. Seebacher C, Kleine-Natrop HE, Kafka G (1973) Die atraumatische Entfernung pilzinfizierter Nägel durch örtliche Anwendung von Kalium jodatum. Dermatol Monatsschr 159: 631-636.
33. Seebacher, C., Blaschke-Hellmessen, R.: Mykosen - Epidemiologie - Diagnostik - Therapie. Jena, Gustav Fischer 1990.
34. Seebacher, C. (2001) Dermatomykosen - Grundlagen und Therapie. In: Schäfer-Korting M (Hrsg.) Optimierte Arzneimitteltherapie. Berlin Heidelberg New York, Springer.
35. Seebacher, C. (2003) Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis. Mycoses 46: 506-510.
36. Shuster S (1988) Onychomycosis: Making sense of the assessment of anti-fungal drugs. Acta Derm Venereol 78: 1-4.
37. Sigurgeirsson B. (2001) Prognostic factors for the treatment of onychomycosis in the long term. JEADV 15 (Suppl.2) 98.
38. Sigurgeirsson B, Olafsson JH, Steinsson JP, Paul C, Billstein S, Evans EG (2002) Long-term effectiveness of treatment terbinafine vs itraconacole in onychomycosis. A 5-year blinded prospective follow-up study. Arch Dermatol 138: 353-357.
39. Tietz HJ, Sterry W (2006) Antimykotika von A-Z. Georg Thieme, Stuttgart New York.
40. Tosti A, Piraccini MB, Stinchi C, Colombo MD (1998) Relapses of onychomycosis after successful treatment with systemic antifungals: A three-year follow-up. Dermatology 197: 162-166.
41. Zaug M, Bergstraesser M (1992) Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 17 (Suppl. 1): 61-70.